Viamet Pharmaceuticals Holdings, LLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Viamet Pharmaceuticals Holdings, LLC
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
Scynexis highlights enrollment exceeding expectations in Phase III VVC trials; Daré prepares to enter Phase III to treat BV.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2018.
Alder ended a patent dispute with Teva with a deal that will enable it to take its Phase III migraine candidate forward, while Sanofi restructures pair of partnerships with Alnylam and Regeneron heading into the J.P. Morgan Healthcare conference – where despite a flow of mid-stage deals, stakeholders are hoping US tax reform means bigger deals to come.
- Other Names / Subsidiaries
- Viamet Pharmaceuticals, Inc.
- VPS-1, Inc.
- VPS-2 Inc.
- VPS-3 Inc.